The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Is there a genomic fingerprint of Radon (Rn)-induced lung cancer (LC)? Comparison of genomic alterations in LC specimens from high and low Rn zones.
 
Hina Khan
No Relationships to Disclose
 
Harish Saiganesh
No Relationships to Disclose
 
Adam J. Olszewski
Research Funding - Genentech/Roche (Inst); Spectrum Pharmaceuticals (Inst); TG Therapeutics (Inst)
 
Yasmine Baca
No Relationships to Disclose
 
Michaela Kastura
No Relationships to Disclose
 
John Vatkevich
No Relationships to Disclose
 
Nimesh Patel
No Relationships to Disclose
 
Humera Khurshid
No Relationships to Disclose
 
Ariel E. Birnbaum
No Relationships to Disclose
 
Stephen V. Liu
Consulting or Advisory Role - Apollomics; ARIAD; AstraZeneca; Bristol-Myers Squibb; Celgene; G1 Therapeutics; Genentech; Guardant Health; HERON; Ignyta; Inivata; Janssen Oncology; Lilly; Loxo; Merck; MSD Oncology; Pfizer; PharmaMar; Regeneron; Roche; Taiho Pharmaceutical; Takeda; Tempus
Research Funding - Alkermes (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); Debiopharm Group (Inst); Esanex (Inst); Genentech/Roche (Inst); Ignyta (Inst); Lilly (Inst); Lycera (Inst); Merck (Inst); Molecular Partners (Inst); OncoMed (Inst); Pfizer (Inst); Rain Therapeutics (Inst); Threshold Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; Roche/Genentech
 
Hirva Mamdani
Consulting or Advisory Role - AstraZeneca; Tempus
Travel, Accommodations, Expenses - AstraZeneca; Caris Life Sciences; Takeda
 
Chul Kim
Consulting or Advisory Role - Novartis
Research Funding - AstraZeneca; Bristol-Myers Squibb; Karyopharm Therapeutics; Novartis; Regeneron; Tesaro
 
Ari M. Vanderwalde
Consulting or Advisory Role - Bristol-Myers Squibb; Caris Life Sciences; Caris Life Sciences; Compugen; Concerto HealthAI; Elsevier; Genentech/Roche; Immunocore
Research Funding - Amgen (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Caris Life Sciences (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Polynoma (Inst); Replimune (Inst)
 
Luis E. Raez
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Heat Biologics (Inst); Loxo (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Syndax (Inst)
 
Mark A. Socinski
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Genentech; Guardant Health; Lilly; Merck; Roche/Genentech
Consulting or Advisory Role - AstraZeneca/MedImmune; Genentech; Lilly
Speakers' Bureau - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech
Research Funding - AstraZeneca/MedImmune (Inst); Genentech (Inst); Spectrum Pharmaceuticals (Inst)
 
Gilberto Lopes
Honoraria - Boehringer Ingelheim
Consulting or Advisory Role - AstraZeneca; Pfizer
Research Funding - Abbvie (Inst); adaptimmune (Inst); AstraZeneca; AstraZeneca (Inst); Bavarian Nordic (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); NOVARTIS (Inst); Pfizer (Inst); Rgenix (Inst); Roche (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; E.R. Squibb Sons, LLC; Janssen; Pfizer
 
Sachin Gopalkrishna Pai
Consulting or Advisory Role - Caris Life Sciences
 
Jorge J. Nieva
Stock and Other Ownership Interests - Cansera; Epic Sciences
Consulting or Advisory Role - AstraZeneca; Fujirebio Diagnostics; Takeda; Western Oncolytics
Research Funding - Merck
Patents, Royalties, Other Intellectual Property - Patent Pending - movement and unexpected healthcare encounters
 
Christopher G. Azzoli
No Relationships to Disclose
 
Howard Safran
No Relationships to Disclose